ClinicalTrials.gg
Not yet recruitingNCT07765862NEOFIXUpdated Oct 23, 2026

A Prospective, Randomized, Two-Arm, Controlled, Single-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of ArtiFix® Dural Repair Sealant Graft in Cranial and Spine Surgery (NEOFIX Study)

An interventional study of ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries. and Standard of Care (Investigator Choice) in CerebroSpinal Fluid (CSF) Leak and Dural Tear, sponsored by Nurami Medical Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Nurami Medical Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of the NEOFIX study is to evaluate the safety and efficacy of ArtiFix® dural sealant graft in comparison to usual treatment for Dural repair (membrane that covers the brain and spinal cord) following cranial and spine surgeries. The investigated device will be implanted during the neurosurgical procedure and participants will be evaluated at 16, 36 and 120 days after the procedure.

02

Conditions studied

  • CerebroSpinal Fluid (CSF) Leak
  • Dural Tear
03

In context

Lead sponsor

Nurami Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-operative inclusion criteria:

  1. Male or female aged ≥18 and \<80 years.
  2. Subject is scheduled for an elective cranial or spine surgery with a potential[EG4.1] dural defect that can be repaired by ArtiFix® graft or Control. The maximal estimated dural defect is 25cm2 with an intact dural margins of at least 5 mm surrounding the defect.
  3. Subject has undergone MRI or CT that includes the planned implantation area in the past 6 months before screening.
  4. Surgical wound is expected to be Class I/clean.
  5. Subject understands the study requirements and procedures and provides written before any study-specific tests or procedures. Subject is able and willing to adhere to the follow-up visits and tests.

    Intra-operative Inclusion criteria:

  6. CSF leakage is observed from the dural defect, either spontaneously or during a Valsalva maneuver.
  7. The ArtiFix® or control can cover a maximum dural defect size of 25 cm². The dural defect must be suitable for coverage with at least 5 mm of intact dural surface surrounding the defect.

Exclusion criteria

Exclusion Criteria:

Pre-operative exclusion criteria:

  1. Dural gap is ≤ 2 mm in cranial procedures. In spine procedures the minimal dural gap is not limited.
  2. Subject is unable to undergo MRI after the surgery (only closed bore MRI is allowed; open bore is not allowed).
  3. Subject is an acute cranial or spine traumatic surgical case or diagnosed as nontraumatic hemorrhagic CVA that requires urgent craniectomy.
  4. Subject is operated to repair Chiari malformation, or with a transsphenoidal approach, or that their surgery involves penetration of air cells, of any kind.
  5. Subject had a previous surgery in the same anatomical site.
  6. Subject has known hydrocephalus or other CSF obstruction disorder or has been treated for hydrocephalus with shunt insertion in the past 10 years.
  7. Subject is currently or was diagnosed in the past 5 years with , excluding basal cell carcinoma or low-grade tumors (i.e., meningioma, ependymoma, schwannoma, hemangioblastoma and other tumors defined as low grade, are eligible to participate).
  8. Intra-operative Valsalva maneuver poses a risk to the subject, as determined by the surgeon or the anesthesiologist.
  9. Subject has a local or systemic infection (e.g. urinary tract infection, active pneumonia) or evidence of any surgical site infection, fever > 38.3℃, or positive blood culture.
  10. Subject has a compromised immune system or an active disease, or is on agents, long term anti-inflammatory biological agents or is on chronic systemic treatment (excluding peri-operative steroid treatment).
  11. Subjected is diagnosed with sepsis, or systemic collagen disease.
  12. Subject at high risk of delayed or failed wound healing due to past treatments or conditions.
  13. Subject has been diagnosed with kidney failure regardless of grade, as evident by serum creatinine levels >1.3 mg/dL.
  14. Subject was diagnosed with liver disease evident by any of the following test results: > 55 U/L, AST > 48 U/L, ALP > 129 U/L, GGT > 61 U/L, Total > 1.3 mg/dL, Albumin \< 3.5 g/Dl, > 1.2, or PT > 15 sec.
  15. Subject has been diagnosed with an uncontrolled diabetes mellitus, as evident by > 7%, or suffered recurrent episodes of hypoglycemia in the past 2 months.
  16. Subject had chemotherapy and/or radiotherapy in the past 8 weeks before surgery or is planned to have chemotherapy or radiotherapy less than 8 weeks after surgery.
  17. Subject requires an external ventricular or lumbar CSF drain that must be left in place after surgery.
  18. Subject has congenital or acquired coagulopathy.
  19. The subject was classified as exhibiting drug abuse.
  20. Subject has any condition that, in the Principal Investigator's judgment, may compromise the subject's safety or preclude compliance with the study investigation plan and/or device instructions.
  21. Subject is participating in another clinical trial that tests any other drug or device.
  22. Subject is pregnant or breast-feeding at screening or intends to become pregnant during the study period.
  23. Subject has known history of sensitivity or allergy to any component of the ArtiFix®.

    Intra-operative Exclusion criteria:

  24. Dural gap is ≤ 2 mm in cranial procedures. In spine procedures the minimal dural gap is not limited.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    ArtiFix the investigational device

    Device: ArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.

  • Active comparator
    Standard of care treatment

    Device: Standard of Care (Investigator Choice)

Interventions

  • DeviceArtiFix® is a surgical dural sealant graft intended to close dural defects following cranial and spine surgeries.

    ArtiFix® is a sterile, synthetic, single use, adhesive, resorbable sealant graft intended to seal and repair dural defects following cranial or spinal surgeries.

  • DeviceStandard of Care (Investigator Choice)

    Standard-of-care for dural repair in spine or cranial procedures (only FDA cleared graft devices and approved sealants will be used)

06

What researchers measure

Primary outcomes

  1. The absence of device-related CSF leakage or re-operation of the implantation site within 120 days after implantation.

    Time frame: at 120 days after ArtiFix® or control implantation

  2. The absence of device-related CSF leakage or re-operation of the implantation site within 120 days after implantation.

    Time frame: at 120 days after ArtiFix® implantation.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 14, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and oversight details
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: identifiers and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07765862
Lead sponsor
Nurami Medical Ltd
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Amir Bahar
Contact
amir@nurami-medical.com
+972-54-4487673
Jenny Krupko
Contact
jenny@nurami-medical.com
0505968319
Joseph Milbaum, MD
study director · Nurami Medical

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion